136 related articles for article (PubMed ID: 8051732)
1. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.
Ellerhorst JA; Kilbourn RG; Amato RJ; Zukiwski AA; Jones E; Logothetis CJ
J Urol; 1994 Sep; 152(3):841-5. PubMed ID: 8051732
[TBL] [Abstract][Full Text] [Related]
2. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
3. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
[TBL] [Abstract][Full Text] [Related]
5. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
6. Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.
Sertoli MR; Brunetti I; Ardizzoni A; Falcone A; Guarneri D; Boccardo F; Martorana G; Curotto A; Sicignano A; Rosso R
Am J Clin Oncol; 1989 Feb; 12(1):43-5. PubMed ID: 2492141
[TBL] [Abstract][Full Text] [Related]
7. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
8. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
[TBL] [Abstract][Full Text] [Related]
9. [Cytokine therapy of metastatic renal cell carcinoma].
Otto T; Goepel M; Luboldt HJ; Rübben H
Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
[TBL] [Abstract][Full Text] [Related]
10. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
12. Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.
Aulitzky WE; Lerche J; Thews A; Lüttichau I; Jacobi N; Herold M; Aulitzky W; Peschel C; Stöckle M; Steinbach F
Eur J Cancer; 1994; 30A(7):940-5. PubMed ID: 7946588
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: a pilot study.
Satake I; Tari K; Nakagomi K; Ozawa K
Jpn J Clin Oncol; 1993 Dec; 23(6):356-62. PubMed ID: 8283789
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies].
Otto U; Schneider A; Denkhaus H; Conrad S
Onkologie; 1988 Aug; 11(4):185-91. PubMed ID: 3141856
[TBL] [Abstract][Full Text] [Related]
15. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
[TBL] [Abstract][Full Text] [Related]
16. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group.
Elhilali MM; Gleave M; Fradet Y; Davis I; Venner P; Saad F; Klotz L; Moore R; Ernst S; Paton V
BJU Int; 2000 Oct; 86(6):613-8. PubMed ID: 11069364
[TBL] [Abstract][Full Text] [Related]
17. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma.
Cancer; 1987 Sep; 60(5):929-33. PubMed ID: 3111677
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
